Our Story:
Who We Are

Redefining Hope through RNA Therapies

At Creyon, we are redefining what’s possible in RNA drug design and delivery. Creyon is a drug development company creating tissue-specific, RNA-targeted nucleic acid therapies that are designed to be safer, more effective, and improve the patient experience. Our focus is on conditions where conventional therapies are limited in their ability to be delivered to the right place, at the right dose, for the right amount of time including immunology, central nervous system (CNS), and neuromuscular disease.

Mission

Our purpose is to unlock the full therapeutic potential of RNA therapies through precise delivery and a deep understanding of tissue biology, enabling better outcomes and improved quality of life for patients.

Board of Directors:

Guiding Creyon’s Vision and Growth

Creyon’s Board of Directors brings together accomplished leaders with decades of experience in biotech innovation, finance, company building, and capital markets. Their collective insight helps guide Creyon’s strategy as the company advances from discovery toward clinical validation and long-term value creation. Our Board members have led or supported successful biotechnology companies through every stage of growth from early-stage formation and platform validation to global partnerships, IPOs, and acquisitions. Their expertise spans corporate strategy, scientific innovation, and financial stewardship, ensuring that Creyon continues to operate with focus, discipline, and momentum.

Kiersten Stead, PhD, MBA

Managing Director, DCVC Bio
Kiersten is a scientist-investor focused on developing deep-tech platforms in therapeutics, agriculture and food, and industrial biotechnology. She works with entrepreneurs... Read More
Kiersten Stead, PhD, MBA
Managing Director, DCVC Bio

Kiersten is a scientist-investor focused on developing deep-tech platforms in therapeutics, agriculture and food, and industrial biotechnology. She works with entrepreneurs to help them launch their businesses at their foundation and/or to support them through successive stages.

Prior to co-founding DCVC Bio, Kiersten was an investor for a major life-science firm, was a scientist, and has co-founded a series of life-science companies over her career. Kiersten serves on several company boards, and as a director on not-for-profit boards such as the Danforth Center for Plant Sciences and the Keystone Symposia SAB. She holds a PhD in molecular biology and genetics and an MBA from the University of Alberta.

Shaquille Vayda

Partner, Lux Capital
Shaq is a partner at Lux Capital, with a passion for technology and a desire to invest in people. He... Read More
Shaquille Vayda
Partner, Lux Capital

Shaq is a partner at Lux Capital, with a passion for technology and a desire to invest in people. He is drawn to technologies that separate true signal from background noise, a theme that has guided him from early DSP work at NASA and Northrop Grumman – where he helped process infrared & RF data for missions like the James Webb – to decoding genomic information at Illumina and observing the birth of GRAIL’s liquid-biopsy platform. And most recently at Parthenon, where he advised mega-cap private equity investors on enterprise & infrastructure software buyouts.

Shaq’s intersectional journey sharpens his view of how foundational “building blocks” in sensing, data, and biology create outsized downstream markets. Shaq serves on the boards of Creyon, Enveda, Atavistik, Nomic, and Gandeeva. He holds a BS in Mechanical Engineering from the University of Florida.

Dennis Langer, MD, JD

Independent Board Director
Dr. Langer has served as a Director of Creyon Bio, Inc. since 2021. He has over 40 years of leadership... Read More
Dennis Langer, MD, JD
Independent Board Director

Dr. Langer has served as a Director of Creyon Bio, Inc. since 2021. He has over 40 years of leadership experience in the pharmaceutical and biotechnology industries, is known for his dual medical and legal background, and has played a role in developing or commercializing over 60 products. He has held senior executive positions at major pharmaceutical companies, biotechnology companies, and venture capital, and has served on numerous corporate boards. After serving at Eli Lilly, Abbott Laboratories (where he identified and repositioned Depakote for bipolar disorders) and Searle (where he supervised the launches of Ambien for insomnia and Calan SR for hypertension), he served as a Senior Vice President in R&D at SmithKline Beecham and GlaxoSmithKline. Subsequently, he was Co-Founder and Director of Ception Therapeutics, Inc., which licensed an IL-5 antibody from Schering for eosinophilic asthma, was acquired by Cephalon, Inc., and the product is now commercialized in the U.S. and Europe. Previously, he was President, North America for Dr. Reddy’s Laboratories, Managing Partner, Phoenix IP Ventures, and the Founding CEO of Neose Technologies (Nasdaq:NTEC). He is currently a Director of Quoin Pharmaceuticals (Nasdaq:QNRX), Empirico, Inc., Braeburn, Inc., Whitehead Institute for Biomedical Research, and the Harvard Law School Dean’s Advisory Board. Previously, he served on the Boards of Myriad Genetics (Nasdaq: MYGN), Transkaryotic Therapies (Nasdaq: TKTX), Sirna Therapeutics (Nasdaq: SRNA), and Dicerna Pharmaceuticals (Nasdaq: DRNA). He received his M.D. from Georgetown University School of Medicine, his J.D. from Harvard Law School, and his B.A. in Biology from Columbia University in New York City. He was an Intern, Resident, and Chief Resident at Yale, and served Fellowships at the National Institutes of Health and Harvard/Children’s Hospital of Boston.

Culture:

United by Purpose, Driven by Science in the Service of Patients

At Creyon, our culture is built around a simple idea that groundbreaking science can only happen when people are inspired by a shared purpose. We’re driven by the belief that every experiment, every idea, and every discovery brings us closer to improving patients’ lives for the long term.

Our work doesn’t stop at the bench. We are building a company where curiosity fuels innovation, compassion guides our mission, and collaboration amplifies our impact.

Delivery is at the core of what we do—how we execute and how our science works. This process is required to get patients new therapeutics, improve treatment, or treat diseases that are currently untreatable.

RNA breakthroughs is what Creyon was founded upon. We are dedicated to making patient-meaningful improvements to RNA therapeutics.

Redefining how patients feel today and tomorrow. We are working to change the lives of patients by reimagining the drug delivery and discovery process and redefining what is possible.

Hope is not passive. We are empathetic and future-focused. Our work fuels our dedication, innovation, collaboration, and ethical responsibility to deliver breakthroughs for those with unmet medical needs.

Creyon is more than a biotech company

We are a community of scientists, engineers, and innovators who care deeply about the people our work will help one day. We approach science with the same humanity we aim to bring to healthcare. We are thoughtful, accountable, and hopeful.

Our team thrives on candor, collaboration, and ownership. Candor eliminates hierarchy so ideas can be evaluated on their merits, leading to clearer thinking and higher-quality decisions. Collaboration eliminates silos and enables an integrated approach to problem-solving, ensuring we leverage the strengths and diverse perspectives of our team. Ownership requires the courage to make bold bets, the discipline to execute, and a commitment to empowering others with speed and accountability.

This website uses cookies to enhance your browsing experience and ensure the site functions properly. By continuing to use this site, you acknowledge and accept our use of cookies.

Accept All Accept Required Only